HOME >> BIOLOGY >> NEWS
Enzyme inhibitor produces stable disease in patients with advanced solid cell cancers

Prague, Czech Republic: Preliminary trials of a MEK enzyme inhibitor have shown that it is capable of producing long-lasting stable disease in patients with advanced solid cancers. Tests showed that the drug inhibited key targets in the patients' tumours, and now it is being tested in phase II clinical trials.

Professor Alex Adjei told the EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Prague today (Wednesday 8 November) that the drug AZD6244 (ARRY-142886) [2] inhibited MEK1/2 an enzyme that plays an important role in the Ras/Raf/MEK/ERK cell signalling pathway, which regulates cell proliferation and survival. Activation of this pathway has been implicated in a number of cancers, including lung, pancreatic, colon, melanoma and thyroid cancer.

"Laboratory studies have shown that AZD6244 has an effect on human tumours at nanomolar concentrations, and the first part of the phase I clinical trial has determined the maximum tolerated dose and the safety of the compound. Results from this second part of the trial demonstrate that a dose of 100mg of AZD6244 is well tolerated, produces a high incidence of long-lasting stable disease, and is associated with a profound inhibition of the cell signalling protein pERK and a reduction in cell proliferation which indicates that the drug is working against the tumours," said Prof Adjei, who was professor of oncology at the Mayo Clinic, Rochester, USA, before moving in October to be the senior vice-president for clinical research and chair of the Department of Medicine at the Roswell Park Cancer Institute, Buffalo, USA.

Prof Adjei and his colleagues at the Mayo Clinic, University of Colorado Health Sciences Center and Fox Chase Cancer Center recruited into the second part of the trial 34 patients with advanced cancers, including melanoma, breast, lung and colorectal cancers. Approximately 40% of the patients had melanoma. The researchers were particularly intere
'"/>

Contact: Emma Mason
wordmason@mac.com
44-077-112-96986
European Organisation for Research and Treatment of Cancer
8-Nov-2006


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. Enzyme delivered in smaller package protects cells from radiation damage
3. Enzyme Engineering XIX
4. Enzyme shreds Alzheimers protein
5. Enzyme defect leads to hyperinsulinism
6. Eat less, weigh more? Enzyme makes lean mice susceptible to dietary fat
7. Enzyme crystal structure reveals unexpected genome repair functions
8. Enzyme inhibitors block replication of SARS virus
9. Enzyme may be target for new anti-inflammatory compounds
10. Enzyme action creates protein linked to Alzheimers disease
11. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... LONDON (PRWEB) , ... August 15, 2019 , ... ... launch of their Food and Agriculture practice, a new unit dedicated to building 100 ... in sustainable nutrition, raw materials and supply chains. , Deep Science Ventures was ...
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, VP, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common imaging ... , NAFLD is the most common diffuse liver disease, with a worldwide prevalence ...
(Date:8/9/2019)... ... ... With a demand in healthcare to lower unneeded emergency room visits and provide ... in the coming years, according to a new report on the industry by market ... is a detailed look at the current state of these healthcare outlets, including the ...
Breaking Biology News(10 mins):
(Date:8/7/2019)... SOLON, Ohio (PRWEB) , ... August 07, 2019 , ... ... with a breakthrough line of soil amendments (soil “probiotics”), including Rhizolizer ® , ... within a year—the largest impact any approach has offered to date. Results from the ...
(Date:8/6/2019)... ... August 06, 2019 , ... The National Science Foundation (NSF) ... community project that will engage middle and early high school students in environmental ... Citizen Science Network for Community Environmental Assessment.” Collaborative partners presenting the authentic science ...
(Date:7/23/2019)... ... July 22, 2019 , ... While today ... in the fields of 3D tissue imaging , digital pathology , ... started back in 2013 as a products company. These products are focused on ...
(Date:7/17/2019)... ... July 16, 2019 , ... ... development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment ... company, will have dedicated manufacturing space at the new, state-of-the-art commercial manufacturing ...
Breaking Biology Technology:
Cached News: